BioCryst Pharma (BCRX) Reports Q4 Loss Per Share of 6c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.70 +3.20%
EPS Growth %: -43.8%
Financial Fact:
Royalties: 3.5M
Today's EPS Names:
ALZN, ASPU, USAU, More
EPS Growth %: -43.8%
Financial Fact:
Royalties: 3.5M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.06), $0.17 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $9 million versus the consensus estimate of $4.13 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Barclays Starts Tower Semiconductor (TSEM) at Overweight
- BMO Capital Downgrades Linamar Corp (LNR:CN) (LIMAF) to Market Perform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
